Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:AXSM NYSE:BHVN NASDAQ:LEGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$89.25-0.8%$55.05$4.77▼$92.91$6.80B0.581.13 million shs1.20 million shsAXSMAxsome Therapeutics$125.68-2.8%$111.18$75.56▼$139.13$6.45B0.54542,929 shs794,585 shsBHVNBiohaven$14.50+0.1%$14.65$12.79▼$55.70$1.53B1.022.05 million shs1.50 million shsLEGNLegend Biotech$34.25-1.1%$37.85$27.34▼$52.31$6.39B0.28919,644 shs1.32 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.24%+11.07%+28.33%+1,043.58%+628.74%AXSMAxsome Therapeutics+3.29%+6.60%+23.37%+17.63%+38.75%BHVNBiohaven-8.57%-5.59%-1.54%-13.60%-60.72%LEGNLegend Biotech-4.05%-0.32%-6.43%-8.02%-28.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$89.25-0.8%$55.05$4.77▼$92.91$6.80B0.581.13 million shs1.20 million shsAXSMAxsome Therapeutics$125.68-2.8%$111.18$75.56▼$139.13$6.45B0.54542,929 shs794,585 shsBHVNBiohaven$14.50+0.1%$14.65$12.79▼$55.70$1.53B1.022.05 million shs1.50 million shsLEGNLegend Biotech$34.25-1.1%$37.85$27.34▼$52.31$6.39B0.28919,644 shs1.32 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax+2.24%+11.07%+28.33%+1,043.58%+628.74%AXSMAxsome Therapeutics+3.29%+6.60%+23.37%+17.63%+38.75%BHVNBiohaven-8.57%-5.59%-1.54%-13.60%-60.72%LEGNLegend Biotech-4.05%-0.32%-6.43%-8.02%-28.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 3.11Buy$95.146.60% UpsideAXSMAxsome Therapeutics 3.13Buy$177.8641.52% UpsideBHVNBiohaven 3.13Buy$55.71284.24% UpsideLEGNLegend Biotech 2.91Moderate Buy$74.22116.71% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, LEGN, ABVX, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ABVXAbivaxBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$112.009/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy ➝ Strong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.009/2/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$75.008/27/2025LEGNLegend BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$66.008/25/2025LEGNLegend BiotechJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $78.008/19/2025BHVNBiohavenBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $60.008/12/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $30.008/12/2025BHVNBiohavenLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$60.00 ➝ $50.008/12/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$63.00 ➝ $54.00(Data available from 9/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$0.69 per shareN/AAXSMAxsome Therapeutics$495.03M12.67N/AN/A$1.18 per share106.51BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ALEGNLegend Biotech$627.24M10.08N/AN/A$5.70 per share6.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$190.71MN/A0.00N/AN/AN/AN/AN/AN/AAXSMAxsome Therapeutics-$287.22M-$5.07N/A44.57N/A-49.88%-283.22%-33.06%11/11/2025 (Estimated)BHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%11/11/2025 (Estimated)Latest BHVN, LEGN, ABVX, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/11/2025Q2 2025LEGNLegend Biotech-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivax1.291.251.25AXSMAxsome Therapeutics1.661.571.51BHVNBiohaven1.913.823.82LEGNLegend Biotech0.304.714.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%AXSMAxsome Therapeutics81.49%BHVNBiohaven88.78%LEGNLegend Biotech70.89%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AAXSMAxsome Therapeutics22.40%BHVNBiohaven14.60%LEGNLegend Biotech0.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6175.57 millionN/ANot OptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableBHVNBiohaven239105.79 million90.35 millionOptionableLEGNLegend Biotech2,609184.57 million184.53 millionOptionableBHVN, LEGN, ABVX, and AXSM HeadlinesRecent News About These CompaniesLegend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript1 hour ago | seekingalpha.comAlliancebernstein L.P. Purchases 32,101 Shares of Legend Biotech Corporation Sponsored ADR $LEGNSeptember 9 at 4:57 AM | marketbeat.comCinctive Capital Management LP Sells 11,869 Shares of Legend Biotech Corporation Sponsored ADR $LEGNSeptember 8 at 5:47 AM | marketbeat.comNomura Holdings Inc. Buys New Position in Legend Biotech Corporation Sponsored ADR $LEGNSeptember 8 at 4:24 AM | marketbeat.comLegend Biotech Considering Second Listing Outside US: ReportSeptember 6 at 3:37 AM | msn.comLegend Biotech in talks for listing outside U.S., Bloomberg saysSeptember 6 at 3:37 AM | msn.comLegend Biotech (NASDAQ:LEGN) Stock Price Up 5.4% - What's Next?September 5, 2025 | marketbeat.comTrexquant Investment LP Makes New Investment in Legend Biotech Corporation Sponsored ADR $LEGNSeptember 5, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Purchases Shares of 40,400 Legend Biotech Corporation Sponsored ADR $LEGNSeptember 3, 2025 | marketbeat.comFY2025 EPS Forecast for Legend Biotech Lowered by AnalystAugust 31, 2025 | marketbeat.comCantor Fitzgerald Expects Weaker Earnings for Legend BiotechAugust 31, 2025 | americanbankingnews.comThe Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma ExpertiseAugust 30, 2025 | uk.finance.yahoo.comTema Etfs LLC Acquires 40,646 Shares of Legend Biotech Corporation Sponsored ADR $LEGNAugust 30, 2025 | marketbeat.comJump Financial LLC Sells 102,241 Shares of Legend Biotech Corporation Sponsored ADR $LEGNAugust 30, 2025 | marketbeat.comCantor Fitzgerald Reaffirms "Overweight" Rating for Legend Biotech (NASDAQ:LEGN)August 29, 2025 | marketbeat.com170,186 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Purchased by Nuveen LLCAugust 28, 2025 | marketbeat.comLegend Biotech assumed with an Overweight at Cantor FitzgeraldAugust 27, 2025 | msn.comLegend Biotech (NASDAQ:LEGN) Given New $78.00 Price Target at JPMorgan Chase & Co.August 27, 2025 | marketbeat.comLegend Biotech's Surging Revenue Fuels Analyst Confidence Despite Ongoing LossesAugust 26, 2025 | aktiencheck.deALegend Biotech to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 26, 2025 | markets.businessinsider.comPrice T Rowe Associates Inc. MD Trims Stock Position in Legend Biotech Corporation Sponsored ADR $LEGNAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, LEGN, ABVX, and AXSM Company DescriptionsAbivax NASDAQ:ABVX$89.25 -0.75 (-0.83%) Closing price 04:00 PM EasternExtended Trading$89.25 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Axsome Therapeutics NASDAQ:AXSM$125.68 -3.61 (-2.79%) Closing price 04:00 PM EasternExtended Trading$127.08 +1.40 (+1.12%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Biohaven NYSE:BHVN$14.50 +0.01 (+0.07%) Closing price 03:59 PM EasternExtended Trading$14.60 +0.10 (+0.69%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Legend Biotech NASDAQ:LEGN$34.25 -0.37 (-1.07%) Closing price 04:00 PM EasternExtended Trading$34.26 +0.01 (+0.02%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
